236 related articles for article (PubMed ID: 31315829)
1. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
Oza B; Radhakrishna S; Pipalava P; Jose V
J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
[TBL] [Abstract][Full Text] [Related]
4. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Overview on Biosimilars.
Kadam V; Bagde S; Karpe M; Kadam V
Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar insulins: a European perspective.
DeVries JH; Gough SC; Kiljanski J; Heinemann L
Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
[TBL] [Abstract][Full Text] [Related]
8. The Regulation of Biosimilars in Latin America.
Garcia R; Araujo DV
Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
Dranitsaris G; Amir E; Dorward K
Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
[TBL] [Abstract][Full Text] [Related]
10. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
12. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
14. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.
Pineda C; Caballero-Uribe CV; de Oliveira MG; Lipszyc PS; Lopez JJ; Mataos Moreira MM; Azevedo VF
Clin Rheumatol; 2015 Apr; 34(4):635-40. PubMed ID: 25673060
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars.
Sugay J
Clin J Oncol Nurs; 2018 Oct; 22(5):27-32. PubMed ID: 30239528
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
17. On safety margin for drug interchangeability.
Zheng J; Chow SC; Song F
J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in oncology: from development to clinical practice.
Rak Tkaczuk KH; Jacobs IA
Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
[TBL] [Abstract][Full Text] [Related]
19. Biological agents and biosimilars: Essential information for the internist.
Pasina L; Casadei G; Nobili A
Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
[TBL] [Abstract][Full Text] [Related]
20. Why are biosimilars much more complex than generics?
Pagani E
Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
